Abstract:Deep Vein Thrombosis (DVT) has been known as a common medical problem all over the world. Thrombus traveling in blood vessels may lead to pulmonary embolism (PE), associated with high rates of mortality. Anticoagulant therapy is the mainstay treatment of DVT. Common anticoagulants, Vitamin K antagonists (VKAs), unfractionated heparin (UFH) and Low-molecular-weight heparin (LMWH) have been used in clinical application over decades, but can increase the risk of hemorrhage. Thereby, several new oral anticoagulants (NOACs) have been developed, which includes direct thrombin inhibitors (DTI) and direct factor Xa inhibitors. To be contrast with VKAs and UFH, NOACs have many advantages such as rapid offset action, few drug/food interactions and no need for routine coagulation monitoring, etc. Many NOACs are still being evaluated in Phase III clinical trials such as Betrixaban and Darexaban (YM150). However, NOACs still have problems to be solved such as lack of antidotes and laboratory monitoring, high drug costs, etc. Besides, several agents have already shown the potential to be new anticoagulants. Factor Xa play an important role in thrombin generation and coagulation pathway. Thus, the new compounds directly targeting on factor Xa for prevention DVT are highly anticipated. DPC423, a new series of 6-substituted coumarin derivatives and Phenyltriazolinones as potent factor Xa inhibitors have been recently reported. Recent studies revealed that agents extracted from botanicals not only have anti-coagulant effects but also possess other pharmacological activities such as anti-inflammation to alleviate the post-thrombotic syndromes. All the evidence above suggests that many new compounds might have great potential to be more effective and safe oral anticoagulants.

Research progress of oral antithrombotic drugs

Advances in clinical studies of oral anticoagulation

Research advances in the study of anticoagulant active molecules

New Medicine for Antithrombotic Treatment of Atrial Fibrillation—Who Can Dominate in the Future

Research Progress on Thrombin Inhibitor

Progress of thrombus formation and research on the structure-activity relationship for antithrombotic drugs

Mechanisms of thrombosis and research progress on targeted antithrombotic drugs

New challenge of target-specific anticoagulants replacing warfarin

Development of the Basic and Clinical Study of New Thrombolytic Drugs

Chinese Herbal Remedies Affecting Thrombosis and Hemostasis: A Review

Characteristics and clinical research of new oral anticoagulants

Progress in research of P2Y12 receptor antagonists antiplatelet drugs

Developments of Anticoagulants and New Agents with Anti-Coagulant Effects in Deep Vein Thrombosis.

Advances in the research of therapeutic targets and the development of new drugs against arterial thrombosis

Therapeutic effects and molecular mechanisms of natural products in thrombosis

Progression of ADP Receptor Inhibitors Antiplatelet Drugs

Research progress on thrombin binding of GPIb-Ⅸ-Ⅴ complex and related drugs

Research Progress of Low Molecular Weight Heparin

The Progress in the Research of Antiplatelet Agents (1995–2017)

Clinical research progress of antiplatelet drugs

Research Progress of Thrombolytic Enzymes